• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma

    2020-08-18 10:02:14DanieleDondossolaMicheleGhidiniFrancescoGrossiGiorgioRossiDiegoFoschi
    World Journal of Gastroenterology 2020年25期

    Daniele Dondossola, Michele Ghidini, Francesco Grossi, Giorgio Rossi, Diego Foschi

    Abstract Cholangiocarcinoma (CCC) is the most aggressive malignant tumor of the biliary tract. Perihilar CCC (pCCC) is the most common CCC and is burdened by a complicated diagnostic iter and its anatomical location makes surgical approach burden by poor results. Besides its clinical presentation, a multimodal diagnostic approach should be carried on by a tertiary specialized center to avoid missdiagnosis. Preoperative staging must consider the extent of liver resection to avoid post-surgical hepatic failure. During staging iter, magnetic resonance can obtain satisfactory cholangiographic images, while invasive techniques should be used if bile duct samples are needed. Consistently, to improve diagnostic potential, bile duct drainage is not necessary in jaundice, while it is indicated in refractory cholangitis or when liver hypertrophy is needed. Once resecability criteria are identified, the extent of liver resection is secondary to the longitudinal spread of CCC. While in the past type IV pCCC was not considered resectable, some authors reported good results after their treatment. Conversely, in selected unresectable cases, liver transplantation could be a valuable option. Adjuvant chemotherapy is the standard of care for resected patients, while neoadjuvant approach has growing evidences. If curative resection is not achieved, radiotherapy can be added to chemotherapy. This multistep curative iter must be carried on in specialized centers. Hence, the aim of this review is to highlight the main steps and pitfalls of the diagnostic and therapeutic approach to pCCC with a peculiar attention to type IV pCCC.

    Key words: Perihilar cholangiocarncioma; Liver resection; Biliary drainage; Neo-adjuvant therapy; Type IV cholangiocarcinoma; Klatskin tumor

    INTRODUCTION

    Cholangiocarcinoma (CCC) is the most frequent and aggressive malignant tumor of the biliary tract. It arises from the epithelial cells of a bile duct and from their progenitor cells (a group of heterogeneous dynamic cells lining the biliary tree). CCC develops either within the duct or shaping a mass infiltrating the adjacent tissue (mass forming cholangiocarcinoma)[1].

    CCC is commonly classified according to the site of invasion into intrahepatic and extrahepatic, itself divided into hilar/perihilar [or Klatskin tumor, perihilar CCC (pCCC)] and distal. Extrahepatic CCC are the most common among CCC[2]. pCCC is defined as CCC located in the extrahepatic biliary tree proximal to the origin of the cystic duct[3,4]. It is burdened by a complicated diagnostic iter and its anatomical location makes the surgical site less accessible, causing higher unresectable rates[5].

    In this review, we will focus our attention on diagnostic and surgical approach to pCCC in order to underline the key points in its management.

    EPIDEMIOLOGY AND ETIOPATHOGENESIS

    CCC is a heterogeneous group of malignancies that represent the 3% of all gastrointestinal tumors[6]. Among CCC, 75% are extrahepatic CCC and half of them pCCC. The incidence of extrahepatic CCC varies worldwide from 0.3-3.5 per 100000 inhabitants/year in North America to 90/100000 inhabitants/year in Thailand. Among Mediterranean region, the incidence is fixed around 7.5/10000 inhabitants/year[7,8]. In Italy 5400 new cases/year are expected[9]. Extrahepatic CCC represent 1% of new neoplastic diagnosis in male and 1.4% in female, with a reduction in the female sex during the last few years[10]. The median age at diagnosis is 50 years; almost null risk is reported before 40 years, while a peak is registered around 70 years[9].

    The identification of risk factors for pCCC is some-like difficult due to many reasons; first of all, papers do not often distinguish CCC into intrahepatic or extrahepatic and merge CCC with gallbladder carcinomas. Furthermore, cases are frequently isolated with no identifiable risk factors. The published risk factors can be divided in[11,12]: Known: Hepato/choledocholithiasis, hepatitis B and C infection, obesity, diabetes mellitus, congenital hepatic fibrosis, Caroli’s disease or choledocal cyst, primary sclerosing cholangitis (PSC), liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), intrahepatic litiasis and recurrent pyogenic cholangitis; suspect: Inflammatory bowel disease, smoke, asbestos, genetic polymorphisms, diabetes.

    According to these data, a surveillance program can be settled in selected patients using magnetic resonance or endoscopic-retrograde-pancreatoduodenoscopy (ERCP) (Table 1)[13-16].

    The highest relative risk is identified in liver fluke infections (Opisthorchis viverrini and Clonorchis sinensis), endemic in South-East Asia[17]. Infection spreads after the ingestion of contaminated fish; and then the flukes colonize biliary tree causing chronic infection and inflammation.

    Even if the mechanisms causing the transformation of cholangiocyte into neoplastic cells are nowadays unknown, CCC development in PSC is widely investigated. The risk for patients affected by PSC (as well as other diseases of biliary plate,e.g.Caroli’s disease) to develop CCC in their lifetime is around 3%-30%[15]. Pancreatic enzymes reflux, cholestasis and chronic inflammation leads to cholangiocyte activation, apoptosis, progression of senescence pathways and increased cellular turnover. All these mechanisms are involved in carcinogenesis: Some studies underline a common pathway (interleukin 6, cyclooxygenase-2, nitric oxide,etc.) between inflammation and malignant cellular proliferation acting on hepatic progenitor cells[18-20]. Together with this pathogenetic theory, an alternative carcinogenetic mechanism has been introduced: It is based on mitogenic pathway activation with a consequent multistep tumoral development[21]. These two mechanisms cannot be considered mutually exclusive. Indeed, in PSC patients the presence of cholangiocyte dysplasia was demonstrated together with CCC. The analyses of CCC specimens underlined a wide heterogeneity of gene mutations, however they seem to be polled according to a geographical distribution[22].

    CLASSIFICATION AND STAGING

    Macrosopic classification

    The Bismuth classification, after modified by Corlette, is well known between general surgeons (Figure 1)[23]. It is used to try to define the correct surgical approach and it is based on macroscopic tumor appearance at the pre-surgical imaging. Although this classification is largely used in literature, it has different limits: The absence of longitudinal description of the cancer extension, no relation with prognostic data, and no clearly defined resectability criteria[24,25]. Other classifications have been proposed (e.g., Memorial Sloan-kattering Cancer Centre) but none of them supplanted the use of the Bismuth-Corlette one.

    On the other hand, tumor-node-metastasis (TNM) classification is worldwide accepted to define the prognosis[4]. Since the 7thedition of America Joint Commission on Cancer (AJCC) classification, pCCC has been recognized as a separate disease from the distal CCC. Unfortunately, hystopathological evaluation of surgical specimen, together with pre-operative imaging data is needed to define the correct TMN classification. For these reasons, it cannot be used to define resectability during diagnostic iter.

    At the end of 2016, AJCC was revised and the 8thedition of TNM classification was published. Some main changes were introduced in the 8thedition to better depict pCCC prognosis[3,26,27]. T4 stage is no longer linked to Bismuth-Corlette type IV pCCC, as underlined by Ebataet al. T4 pCCC is now defined as a tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery, or unilateral second order biliary radicals with contralateral portal or hepatic artery involvement. According to the current TNM classification, N stage depends on the number of locoregional lymph nodes involved. Furthermore, stage IIIC category was introduced in TNM staging.

    Beside these changings, some comments can be pointed out: Liver parenchymal invasion does not define a metastatic disease (T2b) and represent a more favorable prognostic factor than omolateral vascular invasion (T3); the main portal vein invasion (T4) is not a surgical contraindication, but requires vascular reconstruction. A proper N stage can be achieved, according to the 8thedition, only if at least 15 lymph nodes are detected on surgical specimen. A recent paper by Ruzzenteet al[26], tried to evaluate the performance of the new TNM classification in a Western setting. Surprisingly, in this publication, the T4-staged patients had no increased risk of death compared to T1. Furthermore, the ability to predict prognosis of 8thedition N stage was not improved compared to the previous edition. These differences are probably explained by the biological behavior and surgical approach to pCCC in Western and Eastern countries[28,29].

    Microsopic morphology

    Along with the macroscopic and staging classification, pCCC can be grouped in fourpatterns according to its microscopic morphology[5,20]: (1) Periductal infiltrating: The most common pattern, characterized by an undefined annular thickening of the duct, is frequently associated to perineural and lymphatic invasion; (2) Mixed: Periductal infiltrating associated with a mass forming tumor involving biliary ducts; (3) Intraductal: Mucosal growth associated to segmental bile duct dilatation. biliaryintrapapillary mucinosus neoplasm are included in this pattern; and (4) Papillarymucinosus: This class is characterized by rich mucina secretion that clutter bile ducts. Their diagnosis is frequently associated to liver abscess.

    Table 1 Patients that should undergo to screening programs and the techniques that should be applied

    Figure 1 Schematic representation of extrahepatic and intrahepatic bile ducts (until second order) showing Bismuth-Corlette classification. CCC: Cholangiocarncioma.

    DIAGNOSIS

    Literature identifies the characteristics of an ideal diagnostic iter for pCCC: Noninvasive imaging and characterization of pCCC, correct localization of the tumor, presurgical stadiation and resectability evaluation (vascular invasion and biliary spread)[30]. Once CCC is suspected, patients must be referred to specialized surgical centers to complete diagnosis and settle a correct treatment. An incorrect diagnostic pathway exposes patients to delayed diagnosis or repetition of invasive and useless examinations[31].

    The onset of symptoms is not specific and most of the patients (> 65%-80%) are not resectable at the time of diagnosis[32-34]. pCCC identification can be anticipated by jaundice (90%) or cholangitis (10%). Almost patients subjected to screening are found asymptomatic[5]. A proposed diagnostic flow chart for pCCC is showed in Figure 2.

    Non-invasive diagnosis

    Ultrasound (US) is considered the first line examination. Even if it is weighted by operator-dependent sensitivity and specificity (55%-95% and 71%-96% respectively) in stenosis visualization, US offers valuable information (also using color-doppler) to establish the future diagnostic plan[35-37].

    Computer tomography (CT) and magnetic resonance cholangiographic sequences (MRCP) provide complementary information. CT allows a better definition of local tumor extension, vascular invasion and metastatic disease, but only small details about intraductal extension of pCCC (sensitivity and accuracy of 60% and 92% respectively). However, the introduction of multidetector-row CT (high-resolution) has increased the ability to predict intraductal biliary spread of pCCC[38], in particular when bile ducts are dilated[31].

    MRCP has the best sensitivity and accuracy (92% and 76% respectively) in identifying the extension of pCCC, but alone is not enough to establish a correct surgical strategy (e.g., lack in vascular invasion)[39,40]. The importance of a correct MRCP execution is highlighted in Zhanget al[41]review. Indeed, they demonstrated that inadequate MRCP image leads to the re-execution of the exam and up to 60% of MRCP were found incomplete or inadequate if performed in non-specialized centers.

    Positron-emissions-tomography has a marginal role in pCCC staging. It can be used to identify metastatic lymph nodes, distant metastases or clarify indeterminate lesions, especially in PSC patients[42,43]. Due to its low sensitivity (< 70%), it can be considered only in selected cases: In fact, distant metastasis are better identified using CT, while EUS is the gold standard in lymphnode staging[37].

    Invasive diagnosis

    In selected pCCC cases, diagnosis should rely on invasive examinations: ERCP, percutaneous transhepatic colangiography (PTC), endoscopic ultrasound (EUS). They should be addressed to clarify the nature of a stenosis (biopsy) or to drain bile ducts[5,32,44,45]. Indded, ERCP and PTC are not more relevant than MRCP images in visualizing biliary tree[46,47]. Parket al[48]showed an accuracy for predicting biliary confluence and intrahepatic bile duct involvement of 91%-87% for MRCP and 85%-87% for CT combined with invasive cholangiography.

    Nowadays, PTC is considered a second choice compared to ERCP due to its increased number of complications. However, Zhiminet al[49]described an increased accuracy of PTC (> 90%) in identifying the cranial border of pCCC (especially in pCCC with a proximal localization) compared to ERCP and MRCP.

    Endoscopic ultrasound has a controversial role in pCCC diagnosis and management. It provides accurate information about localization of biliary lesions, peribilary tissue involvement, visualization of lymph nodes, hepatic vessels involvement, and it ultimately allows a proper preoperative staging[5,16,32,44,45,50]. However, EUS and EUS fine-needle-aspiration (FNA) sensitivity is reduced from distal to proximal lesions (100% and 83% respectively)[51]. Definition of N staging using EUS needs further studies: Clinical trials are ongoing to identify the role of lymph nodes FNA in predicting pre-operative N stage[52].

    Cytological sampling can be obtained through brushing or FNA. It is usefull in nonresectable pCCC or before surgery when diagnosis is not confirmed by non-invaisve techiniques[5,44]. EUS-FNA could also be usefull for cases with negative ERCP-examination[53]. The brushing sensitivity ranges from 20%-40%[54,55]while 79%-83% for FNA[51]. Overall specificity is 92%-100% (the number of cases performed in a hospital highly increase specificity and sensitivity)[16,56]. The low global negative predictive value of cytological sampling using ERCP, PTC and EUS does not exclude the presence of pCCC when a non-neoplastic report is given. It is worth highlighting that, although FNA or brushing allows a proper diagnosis, they are charged by an increased risk of seeding. Only small data are reported on this topic[7,52]. Seeding is a major concern especially during EUS FNA: Indeed, the fine-needle crosses duodenal bulb and peritoneal cavity to sample the pCCC. For these reasons, EUS FNA is contraindicated before liver transplantation[16,52].

    Figure 2 Diagnostic and therapeutic work-flow for perihilar cholangiocarncioma.1If cytological confirmation is needed (negative carbohydrate antigen 19-9, positive immunoglobulin G4, and confounding diagnosis at imaging); interrupted line, consider neo-adjuvant therapies. US: Ultrasound; CT: Computed tomography; MR: Magnetic resonance; CA 19-9: Carbohydrate antigen 19-9; BIL: Bilirubin; IgG4: Immunoglobulin G4; ERCP: Endoscopic-retrogradepancreatoduodenoscopy; EUS: Endoscopic ultrasound; FRL: Future remnant liver; PVE: Portal vein embolization; ALPPS: Associated liver partition to portal vein ligation for staged hepatectomy; PTC: Percutaneous transhepatic colangiography; CHT: Chemotherapy; RT: Radiotherapy.

    A further improvement in endoscopic diagnosis is intraductal-EUS. Even if it has almost 91% accuracy[57], it has a lack in tissue sampling and a reduced radial visualization (max 2 cm). Cholangioscopy allows direct visualization of bile duct epithelium and FNA execution and has a sensitivity and specificity of 90% and 96%, and 85% and 100%, respectively[58]. Confocal laser endomicroscopy has high sensitivity, specificity and accuracy (89%-71%-82%[59]). However, many concerns are reported concerning standardization and reproducibility of this diagnostic tool, for this reason it is not suggested for a routine use[16].

    Serum markers

    Carbohydrate antigen (CA) 19-9 is elevated in 85% of pCCC, but it has a variable sensitivity (33%-93%) and specificity (67%-98%) with low positive predictive value (16%-40%). A CA 19-9 cut-off of 129 ng/dL should raise specificity at 70%[2,7,56,60-62]. The main confounding factor is jaundice: A re-evaluation after biliary decompression (BD) is suggested. Another tumor marker is CA-125, but it is seldom used outside clinical trials[7]. Immunoglobulin G4 (IgG4) are specific immunoglobulines produced during IgG4 cholangiopathy, a rare autoimmune disease associated with pancreatitis. The presence of IgG4 suggests IgG4 cholangiopathy, susceptible to steroids’ treatment rather than surgery[63]. New diagnostic approaches are based on liquid biopsy: Detection of cholangiocarcinoma cell-free DNA and circulating tumor cells. Even if some authors reported a usefulness of miRNA measured in bile and blood in pCCC diagnosis, further studies are needed and it probably has a prognostic, more than a diagnostic, role[64-66].

    TO DRAIN OR NOT TO DRAIN

    BD is a key point during diagnostic and therapeutic management of the pCCC patients. A wide debate is open in literature about this topic and BD must be evaluated according to patient clinical conditions.

    Diagnosis and staging in patients with a suspected pCCC are better obtained in absence of foreign bodies in biliary tree. Incorrect indication to BD is one of the most frequent causes of delayed or miss-diagnosis, especially as regards the intraductal extension of the tumor. Hosokawa and colleagues[31]demonstrated that biliary drainage placed before proper diagnosis and staging leads to a higher rate of non-R0 resections. They hypothesized a confounding factor due to artifacts and reduction of the bile duct dilatation.

    Sepsis secondary to cholangitis non-responsive to pharmacological treatment is the only absolute indication to BD. Jaundice, itching or cholangitis are not indications to drain the biliary tree during diagnostic time if the patient is a candidate for liver resection. The use of plastic stents or naso-biliary drainages is more suitable than the use of metallic stents. Indeed the fisrt are easily removed to obtain a correct diagnosis[11,5].

    Once surgical indication is established, biliary decompression is anyway debated. Wide accordance on drainage is achieved when a two-step procedure (two-setp hepatectomy or portal vein embolization followed by hepatectomy) is needed to increase the future remnant liver (FRL) volume. Indeed, standard surgical procedure in pCCC requires the resection of a large portion of “healthy” liver parenchyma and liver hypertrophy could be needed before surgery. When a two-step procedure is programmed, whilst the risk of bacterial colonization is increased, BD can improve FRL hypertrophy[67]and could reduce morbidity and mortality[68,69]. In this setting, Eastern surgeons are more likely to use a naso-biliary drainage[31], while Western specialists prefer endoscopic stents[29].

    Once a one-step hepatectomy is programmed, BD is associated to high risk of septic shock secondary to retrograde cholangitis that could exclude resectable patient from surgery[70]. In a multicenter study, Farges and colleagues[71]reported an increased mortality after BD in patients that underwent left hepatectomy (mainly due to postoperative septic shock) (adjusted OR 4.06, 95%CI 1.01 to 16.3;P= 0.035), while a decreased mortality rate, due to reduction of post-operative liver failure, was observed after right-side hepatectomy (adjusted OR 0.29, 95%CI: 0.11-0.77;P= 0.013). According to their data, the authors suggested that when a right-side hepatectomy is planned in jaundiced patients, BD should be performed and surgery scheduled when bilirubin < 3 mg/dL. Conversely, Celottiet al[72], in their meta-analyses, underlined that patients that underwent pre-operative BD had an increased rate of morbidity and wound infections with no advantages on post-operative mortality. While only a selective use of pre-operative BD is suggested (e.g., patients affected by cholangitis) if one-step hepatectomy is planned, randomized prospective studies are needed to better depict the indications for BD.

    BD can be achieved through percutaneous [Percutaneous Transhepatic Biliary Drainage (PTBD)] or endoscopic (plastic or metallic stent or naso-gastic tube) approach according to hospital expertise. No definitive data are published on the best technique for BD[67]. Table 2 summarizes pros and cons of the two techniques. A recent paper by Higuchiet al[73]estimated a comparable patient survival and morbidity in patients undergoing PTC or ERCP. While increased post-operative tumor dissemination in PTC group is reported, an increased rate of infection is highlighted in ERCP patients[74,75]. Even if some authors reported the overall superiority of PTC on ERCP[74-76], a recent randomized control[77]trial was prematurely stopped due to the higher rate of presurgical mortality among PTC patients (PTCvsERCP: 41%vs11%). Until PTBD the superiority of a technique will be demonstrated, ERCP with endoscopic stent placement should be considered the first line technique to obtain BD[78]. When curative intent resection is not feasible, ERCP must be pursued in a patient oriented approach.

    TREATMENT

    Patient and resecability assessment

    Due to the late onset of symptoms and the aggressive nature of pCCC, less than 50% of the patients are surgically resectable at diagnosis[5]. The main criteria involved in resecability evaluation are highlighted in Table 3.

    A recent paper provides a pre-operative risk score designed to predict the risk of intraoperative metastatic disease or locally advanced pCCC (i.e. unresectable) and the post-operative mortality[79]. Through the evaluation of 566 resected pCCC, the authors identified 5 objective criteria (bilirubin > 2 mg/dL; Bismuth classification at imaging; portal vein and hepatic artery involvement at imaging; suspicious lymph node on imaging) that allow the definition of 4 risk categories. An interesting perspective can be the adoption of this score to define the need for up-front neo-adjuvant chemotherapies in high-risk patients.

    According to the complexity of surgical approach, resectability decision is strictly connected to a careful evaluation of the patient’s performance status, liver, cardiac,respiratory and kidney function[45]. Nutritional status must be evaluated before surgery and all efforts should be directed towards counterbalancing malnutrition progression. Poor nutritional condition leads to reduced survival, increased post-operative complications and prolonged hospital stay[80-82].

    Table 2 Main advantages of two the two techniques available to obtain bile duct drainage

    Table 3 Criteria that can be used to identify non-resectable patients

    Advanced age was identified as one of the main changings in the characteristics of pCCC population. Despite the advanced age, the rate of resectable patients (70%) was similar in octogenarian and non-octogenarian patients. Post-surgical overall survival was not reduced by age even if a carefully selection of patients is needed. Indeed, 30% of octogenarians (vs6% of under 60 years) were excluded to surgery for poor performance status and poor liver function[83].

    Surgical resection

    Curative approach to pCCC relies on free surgical margins. Indeed, after R0 resection, 5-year survival reaches 20%-42% in association or not with chemotherapy[8,5,45,67]. The localization of pCCC is one of the most important factors influencing surgical strategy: Isolated bile duct resection is applicable in Bismuth Corlette type I pCCC, while resection of the bile duct confluence is associated to major hepatectomies in the other types. The quantity of liver parenchyma and the number of segments resected depend on the localization of the cranial border of pCCC: Right hepatectomy + S4 in Bismuth-Corlette type IIIa and left hepatectomy in type IIIb. As surgical procedures (especially in type IIIa) require the resection of more than 50% of the liver, post-surgical hepatic failure must be avoided. FRL and liver functional reserve need to be carefully evaluated through liver functional tests (e.g., indocyanine green clearance), imaging techniques and, if possible, liver biopsy. If the predicted FRL is less than the necessary (< 40% in hepatopatic patients, < 30% in normal liver), a single step hepatectomy is related to an increased risk of liver failure and death[84,85]. A two-step procedure (associated liver partition to portal vein ligation for staged hepatectomy or simple portal vein ligation) or pre-operative portal vein embolization (PVE) must be settled. PVE is largely adopted in the Eastern Countries (55% of the cases compared to the 7% of Western Countries)[29]. A recent study by Leeet al[86]developed a score to evaluate the risk of “small for size” after resection. They included in their analyses FRL, intraoperative blood loss and prothrombine time > 1.2. Olthofet al[69], in the same year, proposed their own score based on FRL, jaundice at presentation, preoperative cholangitis and immediate post-operative bilirubin > 2.9 mg/dL. While the authors underlined that pre-operative BD increases FRL hypertrophy, post-BD cholangitis reduced the positive effect of biliary decompression on post-operative liver failure rate. Even if PVE is more frequently used in Eastern countries, the rate of post-surgical liver failure is similar to Western ones. A more aggressive approach to liver vascular pedicle, a larger lymphadenectomy and an increased rate of intraoperative transhepatic biliary drainage in the Eastern Countries can counterbalance the effect of PVE hypertrophy[87].

    Regardless of the type of hepatectomies, resection of caudate lobe is considered the gold standard. Caudate lobe’s bile ducts open out at bile duct bifurcation and are frequently infiltrated by pCCC. Its removal increases the percentage of R0 resections (59%-87%) with better results in long-term survival (5 years survival from 33% to 44%, resection S1vsnon-resection HR 3.03)[88,89].

    Curative surgical strategies cannot leave aside from a histological intraoperative evaluation of bile duct margins (cranial and caudal). Bile duct R0 resection is one of the most important factors influencing long-term follow-up. If neoplastic cells are detected at frozen section, surgical resection will be enlarged till feasible to obtain R0 (60% of the cases[90]). The growth of pCCC is intraluminal and the perineural spread is frequent. A resection of 1 cm above pCCC localization must be considered in the infiltrative type[91], as well as 2 cm in the papillary/mass-forming[92]. A debate in literature is open to understand the results of high-grade dysplasia detection on bile duct margins. While some studies reported comparable patients’- but reduced disease free – survival, other studies showed a reduced 2 and 5-year disease specific survival in N0 R1-high grade-dysplasia patients (2-year, 76.7%vs84.3%; 5-year, 37.5%vs69.3%)[73,93].

    Portal vein resection can be headed if focal portal invasion (< 2 cm) of the main trunk is demonstrated. Indeed, portal vein resection does not affect post-resection outcome[4,90,94]. Conversely, hepatic artery resection is related to an increased surgical risk, without a demonstrated positive influence on long-term results[95,96].

    In 2012 Neuhauset al[91]proposed a new approach to liver resection in type IIIa pCCC, called “en bloc resection”. In his paper, Neuhaus presented a series of 100 type IIIa pCCC patients that received two different surgical treatements according to the tumor localization: “en bloc resection” in tumors located close to hepatic hilum (n= 50) and standard resection in the others (n= 50). “En bloc resection” consisted in right enlarged hepatectomy + S1, lymphadenectomy and en bloc resection of biliary confluence, extrahepatic bile duct, portal vein bifurcation and right hepatic artery (portal vein reconstruction is needed). 3 and 5-year survival was superior in “en bloc” group (35% and 25%vs65% and 58% respectively) without an increase in surgical complications. Other authors adopted this approach with reported comparable results[97]. The “en bloc resection” is not feasible in left hepatectomy because the no touch approach on hilum is impossible, unless resection and reconstruction of the right hepatic artery are being considered.

    In 2017, Kawabataet al[98]proposed their own surgical technique based on reduced liver manipulation and tumor spread. They described an ab-initio parenchymal transection prior to liver mobilization. Two-year survival was increased in the study group (95%vs58%) with a decrease in surgical complications.

    Bismuth-Corlette Type IV pCCC deserves a peculiar consideration (Table 4). It was considered a surgical contraindication for several years due to the bilateral bile duct invasion. However, in the last few years, the surgical approach to this type of pCCC changed due to the Japanese group’s contributions. In 2018, they published[99]a series of 216 patients with Bismuth Corlette type IV pCCC that underwent surgical resection: R0 resection was achieved in 76.2% of the cases, post-surgical morbidity was 41.6% and the 5-year survival was superior in the resected patients (32.8%vs1.5%). Even if the resection of type IV pCCC is feasible and the results are promising, two main concerns are emerging: An undiagnosed vascular invasion often detected at histopathological evaluation and the high rate of N positive specimens[100,101]. The adoption of an en-bloc approach can be suggested in this type of pCCC to avoidunexpected vascular invasion diagnosis. Furthermore, neoadjuvant chemotherapy can be useful in type IV pCCC to select chemo-responsive tumors, reduce the possible futile resections and improve the extent of R0 rate.

    Table 4 Articles reporting resection of type IV perihilar cholangiocarncioma according di bismuth

    Liver transplantation

    In unresectable pCCC, liver transplantation (LT) can be considered within research protocols and with strict inclusion criteria[102]. These criteria are: Tumor smaller than 3 cm, no evidence of lymph node involvement or metastatic disease, and no prior percutaneous or endoscopic biopsy[103]. The initial results of LT for pCCC were poor. Indeed, overall survival (OS) following LT alone for incidentally diagnosed pCCC in PSC are < 40% at 3-year[104]. LT for pCCC gained new enthusiasm with the publication of Mayo Clinic results: In their studies they identified the risks for disease progression and recurrence, and a multimodal therapy (neoadjuvant chemoradiation therapy is mandatory prior to listing) was successfully applied. In the published series of LT performed at Mayo Clinic, the LT group with neoadjuvant chemoradiation (38 patients) achieved better 1 year (92%vs82%), 3 years (82%vs48%), and 5 years (82%vs21%) overall survival (OS) when compared with the resection group (26 patients). Consistently, the LT group experienced lower post-transplant recurrence (13%vs27%)[105]. Ethunet al[106]compared 191 patients that underwent curative resection with 41 patients that received LT (with Mayo Clinic Protocol) for pCCC. In LT group, 38% of the patients were excluded. Patients who underwent transplant for pCCC showed improved OS compared with resection (5-year: 64%vs18%;P< 0.001). The same results were obtained if patients with tumors < 3 cm with lymph-node negative disease and without PSC patients from resection group (5-year: 54%vs29%;P= 0.03).Resective surgery in pCCC is the standard of care for suitable patients outside the setting of PSC[107]. To date, even if there are no randomized controlled trials, LT after aggressive neoadjuvant therapy (including external beam and transluminal radiation, as well as systemic chemotherapy) seems like an adequate treatment for both unresectable pCCC, as well as pCCC arising in the setting of PSC[108].

    Laparoscopic exploration

    The role of laparoscopic exploration (LE) decreased over time together with the increase of sensibility and specificity of imaging techniques. Routine LE is not recommended, but it can be useful in T2/T3 pCCC according to AJCC classification or type III and IV according to Bismuth-Corlette[92,109]. LE is the only way to detect peritoneal metastasis prior to laparotomy, due to the low predictive value of noninvasive technique. Furthermore, routine opening of the lesser sac during LE can help in detecting metastatic lymphnode of hepatic artery (N2 stage)[110]. A recent meta-analysis[111]collected 8 studies evaluating the role of LE: 32.4% of the patients were found unresectable at exploration with a sensitivity of 56% and a specificity of 100%. In another study, sensitivity of LE increased from 24% to 41% using intraoperative ultrasound[112].

    Lymphadenectomy

    Lymphadenectomy is an essential part of the surgical intervention, as well as bile duct and liver resection. In pCCC, hilar, hepatic artery, portal vein, bile duct, celiac trunk and retroduodenal lymph nodes must be resected. The role of lymphadenectomy is to obtain an adequate post-surgical staging, even if some authors reported a survival benefit[88,113,114]. The 8thedition of TNM classification identifies 15 lymph nodes as the minimum number to obtain an adequate N staging (N1 when 1 to 3 regional lymph nodes are positive, N2 when more than 4 regional lymph nodes are positive)[4]. Regional lymph nodes are located in the hepatic hilum and in the hepatoduodenal ligament (pericholedochal nodes). The first systematic review on lymphadenectomy was published in 2015[115]. Beside AJCC classification, Kambakambaet al[115]rose criticism about the minimum number of dissected nodes. Indeed, in their review, only 9% of the series reported a number of dissected lymph nodes > 15, while N positivity ranged from 31% to 58%[116,117]. Their analyses showed that 7 is the number of lymph nodes that ensures the highest detection rate of N1 and the lowest rate of potentially understated N0 patients. The impact on survival of extended lymphadenectomy (> 15 lymph nodes) is debated, because it does not improve 5-year survival and median OS with an increased rate of surgical complications[5]. The presence of malignant cells within dissected lymph nodes (N1) has a detrimental impact on patient survival: 3-year survival 35%vs10% in N0vsN1 patients[115]. It was recently suggested that the presence of a small number of metastatic lymph nodes (lymph nodal ratio < 0.2 or number of lymph node < 4) does not exclude good long-term survival[114,118].

    Chemotherapy, radiotherapy and palliative treatments

    The role of neo-adjuvant chemotherapy in pCCC is not clearly identified and it is mostly adopted in clinical studies.

    The Mayo Clinic protocol combined neoadjuvant chemosensitization with 5-fluorouracil, external beam radiotherapy plus brachytherapy boost and orthotopic liver transplantation for patients with stage I and II pCCC. In a retrospective series, thirty-eight patients underwent liver transplantation while 54 patients were explored for resection. Patients receiving transplantation had better one-, three- and five-year survival (92%, 82% and 82%) compared to resection (82%, 48% and 21%,P= 0.022). Transplanted patients had fewer recurrences compared to resection (13%vs27%)[105]. The ongoing phase III TRANSPHIL trial is comparing resection with neoadjuvant chemoradiotherapy capecitabine-based and orthotopic liver transplantation[102].

    Resected patients, except the R0 pT1N0M0 ones, as well as non-resected patients must undertake chemotherapy with adjuvant intent. The role of adjuvant chemoradiotherapy is not well defined due to the lack of data from randomized trial[8]. On the contrary, the phase III randomized BILCAP trial, comparing adjuvant capecitabine with observation in resected biliary tract cancers, showed an increased OS for the experimental arm in the protocol-specified sensitivity analysis (adjusting for minimisation factors, nodal status, grade and gender). Specifically, median OS in the capecitabine arm was 53 movs36 mo in the observation group (P= 0.028)[119]. Diversely, the phase III Prodige 12-Accord 18 trial, comparing chemotherapy with oxaliplatin and gemcitabinevsobservation after resection, failed to show an increase in OS (P= 0.74)[120].

    A further phase III study, comparing cisplatin and gemcitabine treatmentvsobservation (ACTICCA-1) is open and recruiting patients[121].

    A meta-analysis evaluating studies of adjuvant chemotherapy, chemoradiotherapy or radiotherapy in biliary tract cancers found a nonsignificant improvement in OS compared with adjuvant treatment compared with surgery alone (P= 0.06). However, patients treated with chemoradiotherapy (OR 0.61) or chemotherapy (OR 0.39) had greater benefit with compared to radiotherapy alone (OR 0.98,P= 0.02) and, specifically, the greatest benefit was in those patients with nodes positive (OR 0.49,P= 0.004) and R1 disease (OR 0.36,P= 0.002)[122]. Another meta-analysis of randomized and non-randomized studies confirmed the improvement in OS given by adjuvant chemotherapy, with a 41% of risk of death reduction compared with observation after resection (HR 0.59,P< 0.0001)[123]. In contrast, a meta-analysis of randomized clinical trials showed no effect of adjuvant treatment on OS improvement (HR 0.91) and a mild improvement in recurrence-free survival (HR 0.83). Neither the lymph-node positive (HR 0.84) nor the surgical margin positive subgroups (HR 0.95) had an OS prolongation with adjuvant treatment[124]. Nassouret al[125]retrospectively analyzed the National Cancer Database to evaluate the role of adjuvant chemotherapy (AT) on pCCC. They found the patients that received AT were younger, with a higher pathological T and N staging, a higher rate of non-R0 resections and a longer hospital stay than patients that did not undergo AT. After a propensity match analyses, they found that AT had a beneficial role on 5-year survival in all resected patients, especially in high risk (non-R0 resection) ones. Furthermore, an advantage on 5-year survival was showed for patient that underwent chemo-radiotherapy compared to chemotherapy alone.

    In case of locally-advanced unresectable disease, the role of radiation therapy remains unclear[8]. A phase II trial compared gemcitabine plus oxaliplatinvschemoradiotherapy with 5-fluorouracil and cisplatin. The trial closed before completion due to slow recruitment, showing an increased median OS (19.9 movs13.5 mo, HR 0.69) and progression free survival (11.0 movs5.8 mo, HR 0.65) for the chemotherapy arm[126]. A small series using image-guided intensity-modulated radiation therapy both in gallbladder and extrahepatic bile ducts cancers demonstrated the feasibility of the procedure, allowing safe dose escalation[127].

    Exclusive chemotherapy remains a suitable option in case of unresectable disease. The phase III UK ABC-02 study has established the cisplatin/gemcitabine chemotherapy as the new standard of care in patients with advanced biliary tract cancer. Median survival was 11.7 for the combination therapy compared with 8.1 mo for the gemcitabine only comparator arm (P< 0.001)[128]. The benefit of the combination was present independent of age (inferiorvssuperior to 65 years), gender, primary tumour site (intravsextrahepaticvsgallbladdervsampullary), stage of disease (locally advancedvsmetastatic) and previous therapy (surgeryvsstenting)[129]. In case of altered renal function, oxaliplatin may be used instead of cisplatin, while in case of poorer clinical conditions, gemcitabine monotherapy may be a choice[8].

    Beyond failure of first line treatment, evidence is scarce. A recent systematic review of the literature gathering 25 non-randomized prospective and retrospective studies reported a median progression-free survival (mPFS) and median overall-survival (mOS) of 3.2 and 7.2 mo, respectively[130]. A large multicenter Italian survey and pooled analysis with published data found a mPFS of 3.1 and median OS of 6.3 mo[131]. Recently, the results of a phase III trial (ABC-06) comparing modified FOLFOX to best supportive care found an advantage in mOS (6.2 movs5.3 mo) with adjusted hazard ratio (HR) 0.69. Patients treated with FOLFOX had a prolongation of median radiological PFS or 4 mo. Moreover, the study showed a 1% rate of complete responses, 4% of partial responses and a 28% of cases had disease stabilization. The overall disease control rate was 33%. Due to the results of this trial, modified FOLFOX should be considered the standard of care in the second-line treatment of BTCs[132].

    Isocitrate dehydrogenase isoenzyme 1 (IDH1) mutations are present in 15% of patients with CCC. Recently, the results of treatment with ivosedinib, an oral smallmolecule inhibitor of mutant IDH1 (mIDH1), have been presented. In patients with mIDH1 progressed to first line treatment, mPFS was 2.7 mo with ivosedinibvs1.4 mo for placebo (HR 0.37,P< 0.001). MOS was 10.8 mo for ivosedinibvs9.7 mo for placebo (10.8 movs9.7 mo for placebo, HR 0.69,P= 0.06). However, mOS for placebo decreased to 6 mo after considering a 57% crossover-rate from placebo to experimental treatment and the difference in mOS between ivosedinib and placebo became statistically significant (HR 0.46,P= 0.0008)[133]. Ivosedinib is the first targeted molecular agent showing efficacy in the treatment of advanced CCC and its use will probably become a standard in the second-line treatment of mIDH1 CCC.

    In patients with an estimated survival longer than 3 mo, bile duct decompression should be reached. Percutaneous or endoscopic approaches are both possibile. ERCP has the advantage of a totally internal stent, without the discomfort of PTBD (less pain and aesthetic impact). On the other hand, endoscopic stents are not easy to arrange in type III and IV pCCC. Percutaneous transhepatic biliary stent placement is an effective alternative to endoscopic stent to relieve cholestasis77. Combined seed intracavitary irradiation with125I can be applied to obtain a better stent patency and survival[134,135].

    OUTCOME AND RESULTS

    Survival after pCCC diagnosis is poor and frequently accompanied by a prolonged hospitalization and a wide use of diagnostic and therapeutic techniques. Median survival is 12 mo in patients not susceptible to surgery and 38 (range 25-40) mo in radically resected patients. Koerkamp and colleagues in 2015[136]evaluated a population of 306 patients that underwent surgical resection for pCCC: Overall 5-year survival was 35%, while it increased to 50% in the 122 (42%) patients N0R0 resection. Excluding R2 patients and patients with intra-hospital death, the median time to recurrence was 31 mo with a 3-year survival after recurrence of 18%. Eastern postoperative survival is slightly better that Western one (median OS of 56 movs43 mo respectively,P= 0.028), depicting a possible more aggressive behavior of pCCC in Western world[29].

    In literature, many variables influence 3 and 5-year survival: Resection margins, type of resection, T stage, N stage, staging, lymphovascular invasion and caudate lobe invasion[88,137,138]. T stage and N positivity are burdened by the highest Hazard Ratios: N1 HR 2.32 (5-year survival N1vsN0 11%vs35%) and T3-4 HR 1.86 (5-year survival T1-2vsT3-4 47%vs19%)[137]. R0 resection was recently underlined as the main factor influencing the outcome, irrespective of the tumor staging[31,139]. Three and five-year recurrence-free survival was 57% and 49% in R0 resection, while 31% and 16% in R1 resection. In stage I, II and III, R0 resection was directly related to segment 1 resection and age > 56 year[31]. Lymphovascular invasion was identified as one of the detrimental prognostic factors on patient and disease free survival. Its role was investigated in lymph nodes positive and negative patients and in both was identified as a detrimental factor[138]. Furthermore, lymphovascular invasion resulted in an increased percentage of patients with lymph nodes metastasis, but not with a decrease in R0 rate, also in Bismuth-Corlette tipe IV pCCC[101,137,140].

    In 2017, van Vugtet al[95]evaluated the impact of vascular invasion on 674 patients affected by pCCC. Median OS was considered independently from curative resection. They found that any hepatic artery involvement is related to poor prognosis (median OS: 16.9 (13.2-20.5) movs10.3 (8.9-11.7) mo,P< 0.001), while unilateral or main portal vein involvement was not related to reduced median OS [14.7 (11.7-17.6) movs13.3 (11.0-15.7) mo,P= 0.116]. This paper confirmed the results provided by other authors and highlighted the necessity of a further modification of the 8thAJCC classification. Indeed, the T4 classification does not discriminate arterial or main portal vein infiltration with a reduced ability to predict patient outcome[26].

    The resection benefits have to deal with the high surgical morbidity and mortality of pCCC. In both Western and Eastern Centre, 90-d surgical mortality ranges around 10%.

    The 5-year survival rate for perihilar cholangiocarcinoma in patients receiving a liver transplant is greater than 70%[105], although these data are affected by selection bias. A number of factors were identified as predictors of outcomes in pCCC liver transplantation: Elevated CA 19-9, portal vein encasement, perineural invasion and absence of vital tumor at explant histopathological examination[140-142]. Recent evidence showed that overall survival is affected by the amount of necrotic tumor after neoadjuvant therapy (patients with minimal response were 9.0 times more likely to die than patients with a complete tumor necrosis) and by lymphovascular invasion[140].

    CONCLUSION

    In conclusion, perihilar cholangiocarcinoma is characterized by high mortality and low rate of resectable patients. The main issue for surgeons is to obtain the most rapid and accurate diagnosis. For this reason, patients must be referred to specialized centers after a suspect diagnosis. Biliary drainage is an important tool in non-resectable patients and in those that are candidate to two-stage hepatectomy. It must be obtained after a definitive diagnosis. Even if surgery represents the only curative option, it is still charged by reduced long-term survival.

    ACKNOWLEDGEMENTS

    Authors would like to thank “Associazione Italiana Copev per la prevenzione e cura dell'epatite virale Beatrice Vitiello- ONLUS” for the valuable support and Erica Bosco for langue review.

    e午夜精品久久久久久久| 亚洲国产欧美日韩在线播放| 国产aⅴ精品一区二区三区波| 久久久久久亚洲精品国产蜜桃av| 久久久精品国产亚洲av高清涩受| 久久九九热精品免费| 美女高潮到喷水免费观看| 一边摸一边抽搐一进一出视频| 亚洲国产欧美网| 亚洲精品乱久久久久久| 国产伦人伦偷精品视频| tube8黄色片| 热re99久久精品国产66热6| 757午夜福利合集在线观看| 久久热在线av| 少妇的丰满在线观看| 国产av又大| tocl精华| 一边摸一边抽搐一进一小说 | bbb黄色大片| 久久精品成人免费网站| 国产成人精品久久二区二区91| av有码第一页| 一二三四社区在线视频社区8| 丰满的人妻完整版| 天天影视国产精品| 午夜免费成人在线视频| 亚洲精品在线观看二区| 天天躁夜夜躁狠狠躁躁| 飞空精品影院首页| 国产99白浆流出| 侵犯人妻中文字幕一二三四区| 美女国产高潮福利片在线看| 国产亚洲精品一区二区www | 亚洲熟妇中文字幕五十中出 | 宅男免费午夜| 久热这里只有精品99| 欧美激情 高清一区二区三区| 高清视频免费观看一区二区| 日韩欧美一区二区三区在线观看 | 两性夫妻黄色片| 十八禁人妻一区二区| 超色免费av| 69av精品久久久久久| 极品教师在线免费播放| 十八禁网站免费在线| 精品国产美女av久久久久小说| 国产淫语在线视频| videos熟女内射| 亚洲国产欧美日韩在线播放| 久久青草综合色| 桃红色精品国产亚洲av| 美女午夜性视频免费| 成年版毛片免费区| 国产精品久久电影中文字幕 | 亚洲精品中文字幕一二三四区| 老司机靠b影院| 亚洲情色 制服丝袜| a级毛片在线看网站| 国产精品香港三级国产av潘金莲| 精品久久久精品久久久| 亚洲成a人片在线一区二区| 亚洲中文av在线| 成人av一区二区三区在线看| 欧美国产精品一级二级三级| 亚洲精华国产精华精| 久久天堂一区二区三区四区| 午夜91福利影院| 色精品久久人妻99蜜桃| 电影成人av| 69av精品久久久久久| 少妇裸体淫交视频免费看高清 | 热99久久久久精品小说推荐| 欧美 日韩 精品 国产| 久久香蕉精品热| 久久精品国产a三级三级三级| 老司机在亚洲福利影院| 99久久99久久久精品蜜桃| 91精品国产国语对白视频| 精品国产乱子伦一区二区三区| 9色porny在线观看| 国产人伦9x9x在线观看| 国产成人欧美在线观看 | 老熟妇乱子伦视频在线观看| 国产成+人综合+亚洲专区| 欧美乱色亚洲激情| 好看av亚洲va欧美ⅴa在| 国产1区2区3区精品| 亚洲精品久久午夜乱码| 两个人看的免费小视频| √禁漫天堂资源中文www| 伦理电影免费视频| 中文字幕最新亚洲高清| 黄色丝袜av网址大全| 正在播放国产对白刺激| 校园春色视频在线观看| 人妻久久中文字幕网| 精品无人区乱码1区二区| 精品一区二区三区四区五区乱码| 亚洲人成伊人成综合网2020| 无人区码免费观看不卡| 欧美色视频一区免费| 欧美人与性动交α欧美精品济南到| 久久精品亚洲av国产电影网| 国产精品成人在线| 高清毛片免费观看视频网站 | 色在线成人网| av在线播放免费不卡| 国产又爽黄色视频| 丁香欧美五月| 精品国产一区二区三区四区第35| av天堂在线播放| 建设人人有责人人尽责人人享有的| 亚洲欧洲精品一区二区精品久久久| 午夜精品在线福利| 一二三四社区在线视频社区8| 老熟妇仑乱视频hdxx| 欧美久久黑人一区二区| 成人手机av| 亚洲中文av在线| 午夜免费成人在线视频| 99国产精品一区二区三区| 夫妻午夜视频| 两性夫妻黄色片| 一级片免费观看大全| 美女高潮到喷水免费观看| 国产精品久久久人人做人人爽| 天天躁狠狠躁夜夜躁狠狠躁| 久热这里只有精品99| 亚洲成av片中文字幕在线观看| 亚洲av日韩精品久久久久久密| 日韩欧美免费精品| 亚洲aⅴ乱码一区二区在线播放 | 一二三四在线观看免费中文在| 国产99白浆流出| videos熟女内射| 精品国产一区二区三区四区第35| 他把我摸到了高潮在线观看| 亚洲第一青青草原| 久久久水蜜桃国产精品网| 亚洲九九香蕉| 亚洲人成电影观看| 欧美日韩一级在线毛片| 国产精品亚洲av一区麻豆| 亚洲精品国产色婷婷电影| 啦啦啦在线免费观看视频4| 亚洲一区二区三区不卡视频| 成年版毛片免费区| 一进一出抽搐gif免费好疼 | 91成人精品电影| avwww免费| 在线天堂中文资源库| 男女之事视频高清在线观看| 中亚洲国语对白在线视频| 免费在线观看黄色视频的| 少妇的丰满在线观看| 国产精品 欧美亚洲| 真人做人爱边吃奶动态| 欧美性长视频在线观看| 下体分泌物呈黄色| 国产一区二区三区视频了| 一级a爱片免费观看的视频| 99热只有精品国产| 精品国产一区二区三区久久久樱花| 久久精品国产亚洲av高清一级| 久久久国产成人免费| 18禁裸乳无遮挡动漫免费视频| 制服人妻中文乱码| 99国产精品99久久久久| 久久人人97超碰香蕉20202| 亚洲国产毛片av蜜桃av| 午夜福利一区二区在线看| 亚洲中文av在线| 99riav亚洲国产免费| 成年女人毛片免费观看观看9 | 欧美乱色亚洲激情| 飞空精品影院首页| 亚洲片人在线观看| 国产男女超爽视频在线观看| 国产精品 国内视频| 国产精品秋霞免费鲁丝片| 国产精品 欧美亚洲| 欧美日韩国产mv在线观看视频| 一区二区三区激情视频| 日韩成人在线观看一区二区三区| 91精品三级在线观看| 18禁美女被吸乳视频| 日本一区二区免费在线视频| 国产片内射在线| 日韩免费高清中文字幕av| 国产成人欧美| 精品视频人人做人人爽| 黄色视频,在线免费观看| 免费观看a级毛片全部| 亚洲avbb在线观看| 黄色毛片三级朝国网站| 一区二区三区激情视频| 久久国产精品男人的天堂亚洲| 国产成人精品在线电影| 最近最新免费中文字幕在线| 亚洲人成伊人成综合网2020| 欧美大码av| 欧美精品啪啪一区二区三区| 女人被躁到高潮嗷嗷叫费观| 精品一品国产午夜福利视频| 成人免费观看视频高清| 夜夜爽天天搞| 99久久精品国产亚洲精品| 久久影院123| 超碰成人久久| 亚洲 国产 在线| 国产91精品成人一区二区三区| 亚洲七黄色美女视频| 香蕉国产在线看| 精品午夜福利视频在线观看一区| 9191精品国产免费久久| 亚洲精品成人av观看孕妇| 啦啦啦免费观看视频1| 午夜福利在线免费观看网站| 国产av又大| 国产亚洲欧美精品永久| 国产成人免费无遮挡视频| 成人av一区二区三区在线看| 久久天堂一区二区三区四区| 欧美日韩乱码在线| 无人区码免费观看不卡| 亚洲情色 制服丝袜| 免费日韩欧美在线观看| 久久人人97超碰香蕉20202| 国产一区二区激情短视频| 久久久久精品人妻al黑| 叶爱在线成人免费视频播放| 精品无人区乱码1区二区| 怎么达到女性高潮| 国产视频一区二区在线看| av欧美777| 亚洲欧美一区二区三区黑人| 丝袜人妻中文字幕| 久久久久国产一级毛片高清牌| 啦啦啦在线免费观看视频4| 一区二区三区激情视频| 国产蜜桃级精品一区二区三区 | 国产99久久九九免费精品| 久久久精品区二区三区| 亚洲国产精品sss在线观看 | 女人被躁到高潮嗷嗷叫费观| 在线免费观看的www视频| 99riav亚洲国产免费| www.熟女人妻精品国产| a级毛片黄视频| 久久久国产欧美日韩av| 国内毛片毛片毛片毛片毛片| 免费在线观看黄色视频的| 亚洲中文日韩欧美视频| ponron亚洲| 99热只有精品国产| 欧美精品一区二区免费开放| 伦理电影免费视频| 欧美日韩精品网址| 成年动漫av网址| 亚洲国产精品一区二区三区在线| 成人国语在线视频| 香蕉久久夜色| 韩国精品一区二区三区| 亚洲熟妇中文字幕五十中出 | av网站免费在线观看视频| 可以免费在线观看a视频的电影网站| 丁香六月欧美| 亚洲精品中文字幕在线视频| 深夜精品福利| 制服诱惑二区| 亚洲色图综合在线观看| 在线观看66精品国产| 欧美精品高潮呻吟av久久| 天堂√8在线中文| 大香蕉久久成人网| 国产成人啪精品午夜网站| 9热在线视频观看99| 国产一区在线观看成人免费| 国产精品自产拍在线观看55亚洲 | 在线观看免费视频日本深夜| 在线永久观看黄色视频| 国产精品 国内视频| 一级片'在线观看视频| 免费日韩欧美在线观看| 亚洲第一av免费看| 高清欧美精品videossex| 一边摸一边做爽爽视频免费| 精品国产美女av久久久久小说| 亚洲av欧美aⅴ国产| 一级片'在线观看视频| a级毛片黄视频| 精品国产一区二区三区四区第35| 日韩欧美免费精品| 首页视频小说图片口味搜索| 高清欧美精品videossex| 婷婷精品国产亚洲av在线 | www.精华液| 亚洲五月色婷婷综合| 亚洲,欧美精品.| 18禁裸乳无遮挡免费网站照片 | 最新在线观看一区二区三区| 一级毛片高清免费大全| 自线自在国产av| 美女高潮到喷水免费观看| 极品人妻少妇av视频| 亚洲自偷自拍图片 自拍| 国产不卡一卡二| 夜夜爽天天搞| av一本久久久久| 变态另类成人亚洲欧美熟女 | 中文字幕av电影在线播放| 12—13女人毛片做爰片一| 国产精品.久久久| 国产欧美日韩综合在线一区二区| 久久 成人 亚洲| 亚洲成人免费av在线播放| 日韩人妻精品一区2区三区| 成人影院久久| 搡老熟女国产l中国老女人| 亚洲色图综合在线观看| 女人被躁到高潮嗷嗷叫费观| 国产男女超爽视频在线观看| 狂野欧美激情性xxxx| 国产精品一区二区在线不卡| 757午夜福利合集在线观看| 欧美日本中文国产一区发布| 高清av免费在线| 亚洲中文字幕日韩| 国产午夜精品久久久久久| 亚洲欧美激情综合另类| 国产精品久久电影中文字幕 | 亚洲情色 制服丝袜| 国产精品久久久久久精品古装| 免费在线观看完整版高清| 精品熟女少妇八av免费久了| 男人操女人黄网站| 免费一级毛片在线播放高清视频 | 欧美黄色淫秽网站| av不卡在线播放| 久热这里只有精品99| 国产成人影院久久av| 久久 成人 亚洲| 精品久久久久久,| 国产精品久久视频播放| 成人影院久久| 国产成人精品无人区| 1024香蕉在线观看| 亚洲aⅴ乱码一区二区在线播放 | 国产深夜福利视频在线观看| 在线观看www视频免费| 侵犯人妻中文字幕一二三四区| 色婷婷久久久亚洲欧美| 日韩大码丰满熟妇| 中国美女看黄片| 欧美老熟妇乱子伦牲交| 日韩视频一区二区在线观看| 免费看十八禁软件| 午夜老司机福利片| 高清av免费在线| 黄色毛片三级朝国网站| 精品福利观看| 色在线成人网| 免费观看人在逋| 亚洲av第一区精品v没综合| 一级作爱视频免费观看| 黄色片一级片一级黄色片| 成人18禁在线播放| 久久国产亚洲av麻豆专区| 老熟妇乱子伦视频在线观看| 亚洲成人免费电影在线观看| 韩国精品一区二区三区| 在线免费观看的www视频| 人成视频在线观看免费观看| 美女 人体艺术 gogo| 免费观看精品视频网站| 亚洲国产精品合色在线| 亚洲伊人色综图| 国产淫语在线视频| 深夜精品福利| 日韩欧美免费精品| 香蕉国产在线看| 成年人黄色毛片网站| 两个人看的免费小视频| 国产乱人伦免费视频| av在线播放免费不卡| 欧美午夜高清在线| 国产成人影院久久av| 老司机午夜福利在线观看视频| 日日爽夜夜爽网站| 亚洲三区欧美一区| 国产在线观看jvid| 欧美日本中文国产一区发布| 中亚洲国语对白在线视频| 很黄的视频免费| 黄色怎么调成土黄色| 国产精品一区二区精品视频观看| 午夜视频精品福利| 精品乱码久久久久久99久播| 久久久久久久精品吃奶| 99热网站在线观看| 一级毛片高清免费大全| 精品国产超薄肉色丝袜足j| 热99久久久久精品小说推荐| 最近最新免费中文字幕在线| 日韩欧美在线二视频 | 亚洲国产毛片av蜜桃av| 亚洲av日韩精品久久久久久密| 男人操女人黄网站| 淫妇啪啪啪对白视频| 超碰成人久久| 嫩草影视91久久| 成年人免费黄色播放视频| 99riav亚洲国产免费| 国产成人啪精品午夜网站| 91九色精品人成在线观看| 老司机靠b影院| 在线免费观看的www视频| 男人操女人黄网站| 脱女人内裤的视频| 国产99白浆流出| 一进一出好大好爽视频| 久久99一区二区三区| 一进一出抽搐动态| 久久青草综合色| 成人av一区二区三区在线看| 捣出白浆h1v1| 日韩有码中文字幕| 亚洲av片天天在线观看| 丝瓜视频免费看黄片| 国产精品九九99| 国产精品成人在线| 欧美大码av| 无限看片的www在线观看| av天堂在线播放| 91成年电影在线观看| 久久午夜亚洲精品久久| 我的亚洲天堂| 黄网站色视频无遮挡免费观看| 午夜福利,免费看| 免费看十八禁软件| 久久热在线av| 侵犯人妻中文字幕一二三四区| 国产欧美日韩一区二区三区在线| 日韩欧美三级三区| 午夜精品在线福利| 精品少妇久久久久久888优播| 老司机靠b影院| 国产精品九九99| 首页视频小说图片口味搜索| 成人永久免费在线观看视频| 纯流量卡能插随身wifi吗| 国产一区二区激情短视频| 久久草成人影院| 国产免费男女视频| 欧美在线黄色| 最近最新免费中文字幕在线| 欧美一级毛片孕妇| 热99国产精品久久久久久7| 波多野结衣av一区二区av| 天堂中文最新版在线下载| 日韩视频一区二区在线观看| 国产成人av教育| 黄色怎么调成土黄色| 欧美+亚洲+日韩+国产| 国产精品.久久久| 国产成人一区二区三区免费视频网站| 精品国产国语对白av| 18禁观看日本| 国产一区二区激情短视频| 国产国语露脸激情在线看| 亚洲av成人一区二区三| 伊人久久大香线蕉亚洲五| 天堂√8在线中文| 亚洲五月婷婷丁香| 精品第一国产精品| 热re99久久精品国产66热6| 日韩欧美三级三区| 亚洲五月婷婷丁香| 99国产精品99久久久久| 亚洲全国av大片| 黄色视频不卡| 两人在一起打扑克的视频| 日韩免费高清中文字幕av| 天天躁狠狠躁夜夜躁狠狠躁| 叶爱在线成人免费视频播放| 免费不卡黄色视频| 亚洲午夜精品一区,二区,三区| 久久国产精品男人的天堂亚洲| 亚洲av熟女| 欧美大码av| 国产欧美日韩一区二区三区在线| 午夜福利免费观看在线| 18禁裸乳无遮挡动漫免费视频| 欧美不卡视频在线免费观看 | 最近最新中文字幕大全免费视频| 国产精品欧美亚洲77777| 亚洲中文字幕日韩| av有码第一页| 精品午夜福利视频在线观看一区| 国产精品1区2区在线观看. | 人人妻人人澡人人爽人人夜夜| 性少妇av在线| 色老头精品视频在线观看| 国产主播在线观看一区二区| 又大又爽又粗| 淫妇啪啪啪对白视频| 久久人人97超碰香蕉20202| 俄罗斯特黄特色一大片| 成年女人毛片免费观看观看9 | 亚洲成人免费av在线播放| 69av精品久久久久久| 黄片播放在线免费| 亚洲av成人不卡在线观看播放网| 少妇裸体淫交视频免费看高清 | 亚洲av成人av| 国产在线精品亚洲第一网站| 久久天堂一区二区三区四区| 美女扒开内裤让男人捅视频| 久久国产精品男人的天堂亚洲| 国产成人欧美在线观看 | 国产国语露脸激情在线看| 国产精品综合久久久久久久免费 | www日本在线高清视频| 成在线人永久免费视频| 精品少妇久久久久久888优播| 午夜福利,免费看| 久久人人爽av亚洲精品天堂| 日韩欧美一区二区三区在线观看 | 美女国产高潮福利片在线看| 女人久久www免费人成看片| 9色porny在线观看| 人妻 亚洲 视频| 国产激情久久老熟女| 欧美在线黄色| 成熟少妇高潮喷水视频| 婷婷精品国产亚洲av在线 | 伊人久久大香线蕉亚洲五| 99热国产这里只有精品6| 身体一侧抽搐| 成年人黄色毛片网站| 国产99白浆流出| 免费观看a级毛片全部| 一进一出抽搐gif免费好疼 | 国产麻豆69| 久久精品国产a三级三级三级| x7x7x7水蜜桃| 久久婷婷成人综合色麻豆| 国产精品偷伦视频观看了| 欧美成人午夜精品| 久久九九热精品免费| 国产成人欧美| 99热国产这里只有精品6| 一进一出抽搐gif免费好疼 | av片东京热男人的天堂| 欧美+亚洲+日韩+国产| 国产精品秋霞免费鲁丝片| 99国产极品粉嫩在线观看| 日本vs欧美在线观看视频| 人人妻,人人澡人人爽秒播| 两人在一起打扑克的视频| tube8黄色片| 国产成人欧美在线观看 | 中出人妻视频一区二区| 国产又爽黄色视频| 国产精品亚洲av一区麻豆| 丁香欧美五月| 国产成人啪精品午夜网站| 精品国产美女av久久久久小说| 国产精品一区二区在线不卡| 亚洲第一青青草原| 国产aⅴ精品一区二区三区波| 少妇被粗大的猛进出69影院| √禁漫天堂资源中文www| 人妻 亚洲 视频| 在线播放国产精品三级| 午夜福利一区二区在线看| www.熟女人妻精品国产| 另类亚洲欧美激情| 国产人伦9x9x在线观看| 国产一卡二卡三卡精品| 两个人看的免费小视频| 一本一本久久a久久精品综合妖精| 亚洲一区高清亚洲精品| 三上悠亚av全集在线观看| 男人操女人黄网站| 欧美亚洲日本最大视频资源| 黄频高清免费视频| 日韩免费高清中文字幕av| 日韩三级视频一区二区三区| 亚洲综合色网址| 日韩 欧美 亚洲 中文字幕| 免费av中文字幕在线| 午夜免费观看网址| 免费观看精品视频网站| 在线天堂中文资源库| 50天的宝宝边吃奶边哭怎么回事| 国产精品二区激情视频| 一级毛片女人18水好多| 国产免费现黄频在线看| 久久精品亚洲精品国产色婷小说| 久久精品国产亚洲av高清一级| 老熟妇乱子伦视频在线观看| 日韩人妻精品一区2区三区| 久久久久久免费高清国产稀缺| 久久九九热精品免费| 每晚都被弄得嗷嗷叫到高潮| 日本wwww免费看| 亚洲美女黄片视频| 欧洲精品卡2卡3卡4卡5卡区| 午夜福利欧美成人| 欧美国产精品一级二级三级| 一进一出好大好爽视频| 精品一区二区三区av网在线观看| 一二三四社区在线视频社区8|